We accomplished this by first, utilizing a single HER4 antibody (E200) which was recently stringently tested and validated in breast carcinoma and second, by developing a standardized semi-quantitative H-Score system for determining HER4 expression status in breast carcinoma. This evidence concerns the gene ERBB4 and breast carcinoma.